NCT03491605 Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
| NCT ID | NCT03491605 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huazhong University of Science and Technology |
| Condition | EBV Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2019-07-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2019-07-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.
Eligibility Criteria
Inclusion Criteria: 1. immunocompetent subjects who was found to have high EBV-DNA load （\>1×103 copies/ml）in peripheral blood during the physical examination 2. Willing to be followed up by telephone or face-to-face interview Exclusion Criteria: 1. Subjects with defined immunodeficiency 2. Subjects who have taken or are going to take immunosuppressive drugs. 3. Subjects Diagnosed a validated hematopathy 4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year. 5. psychological illness which does not allow subjects to understand the study and participate following his own free will 6. Pregnant woman 7. no written informed consent
Contact & Investigator
Jianfeng Zhou, PhD.and MD.
STUDY CHAIR
Director of Department of Hematology in Tongji Hospital，HUST
Frequently Asked Questions
Who can join the NCT03491605 clinical trial?
This trial is open to participants of all sexes, studying EBV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03491605 currently recruiting?
Yes, NCT03491605 is actively recruiting participants. Contact the research team at hj20130318@163.com for enrollment information.
Where is the NCT03491605 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT03491605 clinical trial?
NCT03491605 is sponsored by Huazhong University of Science and Technology. The principal investigator is Jianfeng Zhou, PhD.and MD. at Director of Department of Hematology in Tongji Hospital，HUST. The trial plans to enroll 10,000 participants.